Core Viewpoint - Johnson & Johnson (NYSE: JNJ) has shown significant stock performance, with shares increasing by 53% over the past year and 15% year-to-date, attracting positive attention from analysts like Jim Cramer [2]. Financial Performance - RBC Capital raised Johnson & Johnson's share price target to $255 from $240, maintaining an Outperform rating, citing the company's strong financial position to handle legal challenges [2]. - Bank of America also increased its price target for Johnson & Johnson to $227 from $221, keeping a Neutral rating, and noted that the firm's organic growth is leading to healthier multiples [2]. - The company's projected full-year revenue for 2025 is $94.2 billion, reflecting a 6% growth, with expectations to reach $100.5 billion in 2026 [2]. Analyst Sentiment - Jim Cramer expressed strong optimism about Johnson & Johnson, highlighting the company's cancer drug portfolio and orthopedic spinoff as key factors driving his positive outlook [2][5].

In a statement, MMRDA said, “Some reports and social media posts have suggested a link to an earlier misleading post questioning the structural stability of Metro Line 4 construction. We would like to clarify that this is inaccurate. The visuals used in that misleading post were from a different pier and a different location. Also, today’s unfortunate incident involved the falling of a portion of the parapet.” Expressing regret over the incident, the Maharashtra government agency said a high-level investig ...

The deceased has been identified as Ramdhan Yadav, the Brihanmumbai Municipal Corporation (BMC) said.Other injured individuals have been identified as Rajkumar Indrajeet Yadav (45), who is in a critical condition, Mahendra Pratap Yadav (52), and Deepa Ruhiya (40), who are in stable conditions.The Mumbai Metropolitan Region Development Authority (MMRDA) on Saturday said that the Metro project team is present at the site of the pillar collapse, carrying out the relief operations in close coordination with th ...

经济观察网 基于公开信息，强生（JNJ.US）在2026年有以下值得关注的事件动态，这些事件可能影响 公司运营和市场表现： 业绩经营情况 2026年业绩展望：强生管理层在2026年1月公布的业绩预测显示，2026年运营销售额预计区间为995亿美 元至1005亿美元，调整后每股收益区间为11.43美元至11.63美元，均高于华尔街分析师普遍预期。增长 主要受益于创新药物如TREMFYA、DARZALEX、CARVYKTI等以及医疗科技新品推动。 近期事件 滑石产品诉讼进展：联邦法院针对强生滑石产品与卵巢癌关联的"风向标"审判（Bellwether Trial）预计 最快于2026年下半年启动，该诉讼涉及重大索赔，但公司表示产品安全且将积极应对。 骨科业务分拆计划：强生计划在18至24个月内（从2025年底计）将增长较慢的骨科业务从公司整体业务 中分离，以聚焦高增长领域，这是公司转型战略的一部分。 药品降价协议影响：作为与特朗普政府达成降价协议的16家制药公司之一，强生需消化"数亿美元"的药 品降价冲击，但管理层表示已将其纳入2026年业绩预期，并保持增长韧性。 以上内容基于公开资料整理，不构成投资建议。 ...

A jury in Pennsylvania state court on Friday awarded $250,000 to the family of a woman who sued Johnson & Johnson alleging its talc-based baby powder was to blame for her ovarian cancer, according to an attorney for plaintiffs in nationwide talc litigation against the company.The jury in the Philadelphia Court of Common Pleas sided with family members of Gayle Emerson, who claimed that Johnson & Johnson knew for years its talc-based products were dangerous but failed to warn consumers, according to attorney ...

PHILADELPHIA--(BUSINESS WIRE)--A jury in the Philadelphia Court of Common Pleas has found Johnson & Johnson (NYSE:JNJ) responsible for the company's baby powder products contributing to the death of a Pennsylvania woman. The jury deliberated for more than three days before returning a verdict totaling $250,000 on behalf of the estate of York, Pennsylvania, resident Gayle Emerson, who died as a result of ovarian cancer in November of 2019 after filing her lawsuit six months earlier. The verd. ...

Key TakeawaysJohnson & Johnson (JNJ) was found liable by a Pennsylvania jury for a woman's ovarian cancer, resulting in a $250,000 damages award.Amazon (AMZN)-backed nuclear startup X-energy (via its subsidiary TRISO-X) received U.S. approval for its advanced reactor fuel, a critical step for its small modular reactor (SMR) deployment.UBS (UBS) analysts forecast a massive surge in corporate buybacks, expected to reach $30-50 billion per week through the end of March.Global oil benchmarks settled slightly hi ...

Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]A Johnson & Johnson banner is displayed on the front of the New York Stock Exchange (NYSE) in New York City, in New York City, U.S., December 5, 2023. REUTERS/Brendan McDermid [Purchase Licensing Rights, opens new tab]- Companies- Summary- Trial was second over ovarian cancer since J&J's latest bankruptcy ...

Johnson & Johnson (NYSE:JNJ) is among the most profitable mega cap stocks to buy. On February 6, Johnson & Johnson (NYSE:JNJ) disclosed 12-month pilot-phase data from the OMNY-AF study, which examined the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation (AFib). Announced during the 31st Annual AF Symposium in Boston, the results reveal that investigators achieved 100% acute procedural success with zero adverse events linked to the procedure. As stated by D ...

Johnson & Johnson (NYSE:JNJ) is one of the best medical research stocks to buy according to hedge funds. Johnson & Johnson (NYSE:JNJ) announced 12-month pilot-phase data from the OMNY-AF study on February 6 at the 31st Annual AF Symposium in Boston, evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation. It reported that the initial results for 12-month outcomes across the 30-patient pilot cohort reflect that investigators attained 100% acute proce ...